11:00:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Egetis Therapeutics är ett läkemedelsbolag. Bolaget bedriver idag forskning och utveckling av terapier för behandling av svåra folksjukdomar. Den strategiska inriktningen och fokus är på särläkemedel i sen klinisk utvecklingsfas. Övrigt affärsfokus återfinns inom arbetsområdet som går under behandling av oxidativ stress. Verksamhet innehas huvudsakligen runtom den nordiska marknaden, med sjukhus och kliniker som dominerande kunder. Bolagets huvudkontor ligger i Stockholm.

Kalender

2021-11-04 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-30 Ordinarie utdelning EGTX 0.00 SEK
2021-04-29 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-12-11 Extra Bolagsstämma 2020
2020-11-04 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-04-24 Ordinarie utdelning EGTX 0.00 SEK
2020-04-23 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-18 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning EGTX 0.00 SEK
2019-05-07 Årsstämma 2019
2019-05-06 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning EGTX 0.00 SEK
2018-04-24 Kvartalsrapport 2018-Q1
2018-04-24 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-10-20 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-04-26 Ordinarie utdelning EGTX 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2017-02-10 Extra Bolagsstämma 2017
2016-11-07 Extra Bolagsstämma 2016
2016-10-20 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-04-29 Kvartalsrapport 2016-Q1
2016-04-15 Ordinarie utdelning EGTX 0.00 SEK
2016-04-14 Årsstämma 2016
2016-02-29 Bokslutskommuniké 2015
2015-10-20 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-04-21 Kvartalsrapport 2015-Q1
2015-04-15 Ordinarie utdelning EGTX 0.00 SEK
2015-04-14 Årsstämma 2015
2015-02-17 Bokslutskommuniké 2014
2014-11-14 Extra Bolagsstämma 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-08-28 Kvartalsrapport 2014-Q2
2014-04-25 Kvartalsrapport 2014-Q1
2014-04-09 Ordinarie utdelning EGTX 0.00 SEK
2014-04-08 Årsstämma 2014
2014-02-19 Bokslutskommuniké 2013
2013-10-25 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-04-19 Ordinarie utdelning EGTX 0.00 SEK
2013-04-18 Extra Bolagsstämma 2013
2013-04-18 Årsstämma 2013
2013-04-18 Kvartalsrapport 2013-Q1
2013-03-13 15-7 2013
2013-02-21 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-04-27 Kvartalsrapport 2012-Q1
2012-03-30 Ordinarie utdelning EGTX 0.00 SEK
2012-03-29 Årsstämma 2012
2012-02-17 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2020-10-20 08:00:00

Stockholm, October 20, 2020. The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.

The following members have been appointed by the subsequent shareholders:
Cidro Förvaltning AB: Peter Lindell
Nortal Investments AB: Staffan Persson
Fjärde AP-fonden: Jannis Kitsakis
 
In total, the Nomination Committee represents approx. 31% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Staffan Persson and Jannis Kitsakis are also independent in relation to Cidro Förvaltning AB, which is the largest shareholder in the company in terms of votes.

The Nomination Committee has elected Peter Lindell as chairman. Håkan Åström, Chairman of PledPharma have been nominated to co-opt to the Nomination Committee.

PledPharma AB (publ) signed an agreement to acquire all outstanding shares in Rare Thyroid Therapeutics International AB (RTT) on October 5, 2020. The transaction is expected to be completed on November 3, 2020.

As a part of the share purchase price the former shareholders in RTT will receive 63,773,345 new shares in PledPharma trough an issue of Consideration Shares.

On the occasion of the acquisition of RTT, PledPharma carries out a rights issue of a maximum of 38,238,085 shares. The subscription period is 9 November to 23 November 2020.

The composition of the three largest shareholders will be amended due to the issue of the Consideration shares and the Rights Issue. Therefore, the composition of the future Nomination Committee will also change to reflect the new ownership. PledPharma intends to return with information on the composition of the new Nomination Committee after the new ownership has been registered.

The Committee's assignment is to present proposals regarding Chairman and other members of the, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2022.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com